3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Plasma cell
1
Conditions
Multiple Myeloma
4
Recurrence
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Interventions
fludarabine phosphate
19
fludarabine
18
Cyclophosphamide
16
Tacrolimus
12
Whole-Body Irradiation
11
Melphalan
11
Mycophenolic Acid
10
Bortezomib
9
Busulfan
8
trametinib
7
Dexamethasone
7
thymoglobulin
6
Stem Cell Transplantation
6
Lenalidomide
6
Cyclosporine
6
Sirolimus
5
Nivolumab
5
Methotrexate
5
dabrafenib
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Granulocyte Colony-Stimulating Factor
4
Antilymphocyte Serum
4
Alemtuzumab
4
daratumumab
3
aldesleukin
3
Thiotepa
3
Specimen Handling
3
Ipilimumab
3
Interleukin-2
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
tanespimycin
×
Plasma cell
×
Clear all
NCT00113204
2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1
Completed
18 enrolled